PE Recruiting: M&A vs Rx

Based on the most helpful WSO content, here's the breakdown:

1. Skillset Comparison:

   • RX analysts develop highly technical skills, particularly in modeling, debt schedules, recovery analysis, and understanding complex capital structures. This makes them attractive to distressed-focused PE funds and HFs, as their expertise aligns closely with distressed investing and restructuring scenarios.
   • M&A analysts, on the other hand, focus on broader deal-making skills, including valuation, financial modeling, and transaction execution. These skills are more directly applicable to traditional LBOs and generalist PE recruiting.

2. Exit Opportunities:

   • RX analysts are heavily recruited by distressed PE funds and HFs due to their technical expertise and exposure to creditor dynamics. However, transitioning to traditional buyout PE can be more challenging compared to M&A analysts, as RX work is more niche and less directly aligned with conventional LBO modeling.
   • M&A analysts generally have broader exit optionality, including megafunds, as their experience is more aligned with the typical PE deal process.

3. Perception by Megafunds and Headhunters:

   • While RX analysts are respected for their technical rigor and deep understanding of distressed scenarios, megafunds and headhunters still tend to view M&A as the more direct path to traditional PE roles. This is because M&A analysts typically have more exposure to sponsor-driven deals and conventional acquisition processes.

4. Trends and Considerations:

   • RX is a strong choice if you're targeting distressed-focused funds or want to specialize in restructuring. However, if your goal is broader PE recruiting, M&A might offer better optionality.
   • The rise of liability management exercises (LMEs) and distressed opportunities has increased the relevance of RX skills, but the niche nature of RX work can still limit exit options compared to M&A.

Ultimately, the choice between M&A and RX depends on your career goals. If you're aiming for distressed investing, RX is the clear winner. For broader PE opportunities, M&A remains the safer bet.

Sources: Restructuring prospects, why you should not consider restructuring, Choosing RX over M&A -- anyone recommend this?, Top Restructuring Groups 2019 & Restructuring Questions, Restructuring prospects, why you should not consider restructuring